Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
eSScape: efgartigimod PH20 SC in adults with systemic sclerosis
NL-OMON60310Phase 2Active, not recruiting
- Sponsor
- argenx
- Start
- Nov 2025
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in systemic sclerosis (SSc) comparing Efgartigimod PH20 SC with Placebo PH20 SC (2 arms). Primary endpoint: Change from baseline in modified Rodnan Skin Score at week 24. Started Nov 2025; status: active, not recruiting.
02
Drugs
efgartigimod alfa
03
Conditions
systemic sclerosis (SSc)
Beyond the preview
Go deeper on NL-OMON60310.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60310.